Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Gliclazide 120 mg MR Tablets
NCT02980757Phase 1Withdrawn
- Sponsor
- Disphar
- Start
- Jun 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gliclazide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Disphar. Primary endpoints: Area Under the Curve (0-t) and Maximum Plasma Concentration. Planned start Jun 2014; status: withdrawn.
02
Drugs
gliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02980757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02980757.